CD83 and graft versus host disease: Following the success of A2-targeting CAR Tregs, recent studies have focused on generating CAR Tregs with distinct targeting domains such as CD83 [46], which prevents GvHD in murine models, or CD19, which suppresses B-cell antibody production and pathology leading to GvHD [53].